sanofi q4 - Search News

Sanofi reports Q4 2024 increase in net income to $833m

Sanofi has announced an increase in net income from continuing operations for the fourth quarter (Q4) of 2024, reaching €880m ($833m).

The Motley Fool on MSN · 18h

Sanofi (SNY) Q4 2024 Earnings Call Transcript

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the usual forward-looking statements.

Hosted on MSN · 1d

Sanofi CEO Paul Hudson on Q4 results: We've set ourselves up very well for 2025

Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, 2025 outlook, drug pipeline, the company's dividend and buyback decision, his thoughts on the confirmation hearing of RFK Jr.

SFGate · 1d

Sanofi: Q4 Earnings Snapshot

Sanofi (SNY) on Thursday reported fourth-quarter earnings of $728.6 million. The company said it had net income of 29 cents per share. Earnings, adjusted for non-recurring costs and to account for discontinued operations,

Houston Chronicle · 1d

FirstCash: Q4 Earnings Snapshot

The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of $2.02 per share. The pawn store posted revenue of $883.8 million in the period. For the year, the company reported profit of $258.

Sanofi SA (SNY) Q4 2024 Earnings Call Highlights: Strong Sales Growth and Strategic Investments ...

Sanofi SA (SNY) reports robust sales growth driven by Dupixent and vaccines, while planning a significant share buyback to ...

Sanofi plans share buybacks, signals more deals post Opella sale

Sanofi said on Thursday it would buy back 5 billion euros ($5.21 billion) in shares this year and could be more active with acquisitions in the near term as the drugmaker moves towards selling a large ...

Pharm Exec19h

Roundup: Top Pharma Companies Report Q4 Earnings, Highlighting Revenue Trends and Market Shifts

Q4 earnings for companies such as Johnson & Johnson, Teva, and Roche highlight the impact of significant innovations brought ...

Sanofi Q4 Business Net Income Declines; Net Sales Up 10.3% At CER

Sanofi (SNYNF, SNY) reported fourth quarter net income from continuing operations of 880 million euros compared to a loss of 119 ...

Sanofi Expected to Report Lower Sales, Profit; Size of Buyback in Focus -- Earnings Preview

BUSINESS OPERATING PROFIT FORECAST: Business operating profit--one of the company's preferred metrics, which strips out exceptional items--is forecast at 2.08 billion euros, according to the Vara ...

Teva Pharmaceutical Industries Ltd (TEVA) Q4 2024 Earnings Call Highlights: Strong Revenue ...

Teva Pharmaceutical Industries Ltd (TEVA) reports a 9% revenue increase, driven by innovative and generics business, despite ...

Press Release: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025

Sanofi: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025Paris, January 30, 2025Q4: ...

Sanofi: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025

Sanofi: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025 Paris, January 30, 2025 Q4: sales growth of 10.3% at CER1 and business EPS2 ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results